FDA Asks Pfizer to Test Second Paxlovid Course in Patients With COVID Rebound

The U.S. Food and Drug Administration (FDA) has asked Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.
Reuters Health Information

source https://www.medscape.com/viewarticle/979509?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?